ES2195344T3 - Composicion farmaceutica que presenta una actividad antitumoral mejorada y/o efectos secundarios reducidos, que contiene un agente antitumoral y un derivado de acido hidroximico. - Google Patents

Composicion farmaceutica que presenta una actividad antitumoral mejorada y/o efectos secundarios reducidos, que contiene un agente antitumoral y un derivado de acido hidroximico.

Info

Publication number
ES2195344T3
ES2195344T3 ES98925873T ES98925873T ES2195344T3 ES 2195344 T3 ES2195344 T3 ES 2195344T3 ES 98925873 T ES98925873 T ES 98925873T ES 98925873 T ES98925873 T ES 98925873T ES 2195344 T3 ES2195344 T3 ES 2195344T3
Authority
ES
Spain
Prior art keywords
antitumoral
side effects
acid derivative
reduced side
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98925873T
Other languages
English (en)
Inventor
Balazs Sumegi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
N-Gene Research Laboratories Inc
Original Assignee
N-Gene Research Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by N-Gene Research Laboratories Inc filed Critical N-Gene Research Laboratories Inc
Application granted granted Critical
Publication of ES2195344T3 publication Critical patent/ES2195344T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención se refiere a composiciones farmacéuticas que tienen una mejor actividad antitumoral o efectos secundarios reducidos que comprenden una sustancia activa ya conocida que tiene efecto antitumoral o una sal farmacológicamente aceptable de la misma y un derivado del ácido hidroxímico de la fórmula (I) o una de sus sales de adición ácida terapéuticamente útil.
ES98925873T 1997-06-23 1998-06-22 Composicion farmaceutica que presenta una actividad antitumoral mejorada y/o efectos secundarios reducidos, que contiene un agente antitumoral y un derivado de acido hidroximico. Expired - Lifetime ES2195344T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU9701081A HU9701081D0 (en) 1997-06-23 1997-06-23 Pharmaceutical composition of antitumoral activity

Publications (1)

Publication Number Publication Date
ES2195344T3 true ES2195344T3 (es) 2003-12-01

Family

ID=89995266

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98925873T Expired - Lifetime ES2195344T3 (es) 1997-06-23 1998-06-22 Composicion farmaceutica que presenta una actividad antitumoral mejorada y/o efectos secundarios reducidos, que contiene un agente antitumoral y un derivado de acido hidroximico.

Country Status (25)

Country Link
US (4) US6440998B1 (es)
EP (1) EP0993304B1 (es)
JP (1) JP2002508762A (es)
KR (1) KR20010020496A (es)
CN (1) CN1127984C (es)
AT (1) ATE235918T1 (es)
AU (1) AU735922B2 (es)
BR (1) BR9810312A (es)
CA (1) CA2294913C (es)
CZ (1) CZ298468B6 (es)
DE (1) DE69812949T2 (es)
DK (1) DK0993304T3 (es)
ES (1) ES2195344T3 (es)
HK (1) HK1029941A1 (es)
HU (1) HU9701081D0 (es)
IL (1) IL133508A (es)
NO (1) NO322206B1 (es)
NZ (1) NZ502039A (es)
PL (1) PL191718B1 (es)
PT (1) PT993304E (es)
RU (2) RU2214238C2 (es)
SK (1) SK282877B6 (es)
TR (1) TR199903214T2 (es)
UA (1) UA64757C2 (es)
WO (1) WO1998058676A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884424B2 (en) * 1995-12-22 2005-04-26 N-Gene Research Laboratories Inc. Method for treating the pathological lesions of the skin that develop by ultraviolet radiation of the sunlight
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
DK2368553T3 (en) * 2003-04-08 2015-02-09 Progenics Pharm Inc Pharmaceutical preparation comprising methylnaltrexone
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CA2600350C (en) * 2005-03-07 2015-02-10 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
US7763601B2 (en) * 2006-11-02 2010-07-27 N-Gene Research Laboratories, Inc. Prevention and treatment of obesity
US20080108602A1 (en) * 2006-11-02 2008-05-08 N-Gene Research Laboratories, Inc. Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication
EP3064503A1 (en) * 2007-03-29 2016-09-07 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
ES2765811T5 (es) 2007-03-29 2024-02-27 Progenics Pharm Inc Forma cristalina de bromuro de (R)-n-metilnaltrexona y sus usos
PT2565195E (pt) 2007-03-29 2015-07-28 Wyeth Llc Antagonistas e receptor opióide periférico e respectivas utilizações
CA2704128A1 (fr) * 2007-10-30 2009-07-30 Trophos Nouvelle composition pour traiter les effets secondaires des traitements anticancereux
WO2009074835A1 (en) * 2007-12-10 2009-06-18 N-Gene Research Laboratories Inc. Dose reduction of a cannabinoid cb1 receptor antagonist in the treatment of overweight or obesity
EP2240489A1 (en) * 2008-02-06 2010-10-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
WO2009117669A2 (en) 2008-03-21 2009-09-24 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
ITMI20110793A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
ITMI20110791A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri in grado di metabolizzare gli ossalati.
ITMI20110792A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia.
HUP1100444A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
HUP1100445A2 (en) * 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
RU2522548C2 (ru) * 2012-09-26 2014-07-20 Федеральное государственное бюджетное учреждение науки Институт кристаллографии им. А.В. Шубникова Российской академии наук (ИК РАН) Ингибитор уридинфосфорилаз
US9938279B2 (en) * 2013-04-09 2018-04-10 Energenesis Biomedical Co., Ltd Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK)
CN108703970A (zh) * 2013-09-18 2018-10-26 华安医学股份有限公司 一种活化ampk的化合物及其用途
RU2679136C1 (ru) * 2018-03-13 2019-02-06 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр "Красноярский научный центр Сибирского отделения Российской академии наук" (ФИЦ КНЦ СО РАН, КНЦ СО РАН) Способ получения препарата на основе взаимодействия цис-диамин(циклобутан-1,1-дикарбоксилат-о,о')платины(ii) с арабиногалактаном
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308399A (en) * 1977-08-30 1981-12-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. O-(3-Amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
HUT54347A (en) * 1989-01-10 1991-02-28 Chinoin Gyogyszer Es Vegyeszet Improved process for producing amidoximes
WO1994022480A1 (en) * 1993-03-31 1994-10-13 Merck & Co., Inc. Hiv protease inhibitors in pharmaceutical combinations for the treatment of aids
TW381025B (en) * 1993-08-05 2000-02-01 Hoffmann La Roche Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor
HU9502843D0 (en) * 1995-09-29 1995-11-28 Livigene Ltd Pharmaceutical composition
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells

Also Published As

Publication number Publication date
SK176499A3 (en) 2000-09-12
DE69812949D1 (de) 2003-05-08
RU2214238C2 (ru) 2003-10-20
US20030050345A1 (en) 2003-03-13
PL337719A1 (en) 2000-08-28
IL133508A (en) 2005-11-20
CN1127984C (zh) 2003-11-19
TR199903214T2 (xx) 2000-12-21
NO322206B1 (no) 2006-08-28
DK0993304T3 (da) 2003-07-28
PT993304E (pt) 2003-08-29
HU9701081D0 (en) 1997-08-28
AU7783798A (en) 1999-01-04
US20030069270A1 (en) 2003-04-10
WO1998058676A1 (en) 1998-12-30
EP0993304A1 (en) 2000-04-19
US6720337B2 (en) 2004-04-13
NO996349L (no) 2000-02-23
JP2002508762A (ja) 2002-03-19
CZ298468B6 (cs) 2007-10-10
DE69812949T2 (de) 2004-02-05
US6440998B1 (en) 2002-08-27
CA2294913A1 (en) 1998-12-30
UA64757C2 (uk) 2004-03-15
BR9810312A (pt) 2000-09-19
ATE235918T1 (de) 2003-04-15
KR20010020496A (ko) 2001-03-15
CA2294913C (en) 2008-12-16
SK282877B6 (sk) 2003-01-09
US20020147213A1 (en) 2002-10-10
IL133508A0 (en) 2001-04-30
HK1029941A1 (en) 2001-04-20
RU2254129C2 (ru) 2005-06-20
AU735922B2 (en) 2001-07-19
PL191718B1 (pl) 2006-06-30
US6838469B2 (en) 2005-01-04
US6656955B2 (en) 2003-12-02
CZ462599A3 (cs) 2000-05-17
NO996349D0 (no) 1999-12-20
EP0993304B1 (en) 2003-04-02
CN1263471A (zh) 2000-08-16
NZ502039A (en) 2002-03-28

Similar Documents

Publication Publication Date Title
ES2195344T3 (es) Composicion farmaceutica que presenta una actividad antitumoral mejorada y/o efectos secundarios reducidos, que contiene un agente antitumoral y un derivado de acido hidroximico.
NO962841D0 (no) Anvendelse av 2-hydroksy-5-fenylazobenzosyrederivater som colon cancer kjemopreventativer og kjemoterapeutiske midler
IL153014A0 (en) Barbituric acid analogs as therapeutic agents
TR199903191T2 (xx) Vorikonazol i�eren ila� form�lasyonlar�.
ES2114569T3 (es) Sistema mejorado de penetracion en la piel para la administracion topica mejorada de farmacos.
BR9809304A (pt) "formulações de proteìna c ativada"
ES2133785T3 (es) Inhibidores de metaloproteinasas.
BR9912694A (pt) Composto para preparar medicamento de administração pulmonar
ATE433989T1 (de) Pharmazeutisch wirksame uridinester
DE69940557D1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
IT1314185B1 (it) Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
ATE253359T1 (de) Antithrombotische mittel
PT742716E (pt) Composicao farmaceutica para administracao transdermica sistemica contendo a substancia activa morfina-6-glucuronido
HUP9903369A2 (hu) 8(9)-Dehidroösztradiol-származékok
MY152490A (en) New oral formulation